Nick Xenophon (SA, Independent) Share this | Hansard source

I move:

That the following matter be referred to the Community Affairs References Committee for inquiry and report by 26 March 2015:

The availability of new, innovative and specialist cancer drugs in Australia, with particular reference to:

(a) the timing and affordability of access for patients;

(b) the operation of the Pharmaceutical Benefits Advisory Committee and the Pharmaceutical Benefits Scheme in relation to such drugs, including the impact of delays in the approvals process for Australian patients;

(c) the impact on the quality of care available to cancer patients; and

(d) any related matters.

Question agreed to.